Anke Biotech clinches SFDA approval for TCM clinical trial
Shanghai. April 28. INTERFAX-CHINA - Anhui Anke Biotechnology (Group) Co. Ltd. (Anke Biotech) has obtained approval from the State Food and Drug Administration (SFDA) to conduct clinical trials for its Zhidan Huayu capsule, the company announced April 27.
Anke Biotech holds the intellectual property rights (IPR) to the drug, a traditional Chinese medicine (TCM) used to treat endometriosis (EMT).
The drug will further diversify Anke Biotech's product line for gynecological medical conditions, according to the announcement. The company's product portfolio already includes recombinant human interferon alpha-2b suppository, a biological drug for the treatment of cervical erosion, while another gynecological TCM, Baofukang gel, is currently undergoing clinical trials.
Based in Hefei City, Anhui Province, Anke Biotech produces biological drugs, TCMs and chemical drugs. It launched its initial public offering (IPO) on the Shenzhen Stock Exchange's Growth Enterprise Market (GEM) in October 2009.
- MS